Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH, Garhyan P, Choi SL, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen NK, Sinha VP, Linnebjerg H, Jacober SJ. Mudaliar S, et al. Among authors: garhyan p. Diabetes Obes Metab. 2016 Oct;18 Suppl 2:17-24. doi: 10.1111/dom.12753. Diabetes Obes Metab. 2016. PMID: 27723226 Clinical Trial.
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Porksen N, Linnebjerg H, Garhyan P, Lam EC, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T. Porksen N, et al. Among authors: garhyan p. Diabetes Obes Metab. 2017 Apr;19(4):482-488. doi: 10.1111/dom.12834. Epub 2017 Feb 7. Diabetes Obes Metab. 2017. PMID: 27888561 Clinical Trial.
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Among authors: garhyan p. Diabetes Care. 2016 Nov;39(11):e199-e200. doi: 10.2337/dci16-0030. Diabetes Care. 2016. PMID: 27926898 No abstract available.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Kazda CM, et al. Among authors: garhyan p. Diabetes Care. 2017 Jun;40(6):808. doi: 10.2337/dc17-er06. Epub 2017 Apr 18. Diabetes Care. 2017. PMID: 28420698 Free PMC article. No abstract available.
27 results